# SunRISe-5 (NCT06211764)

> A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06211764
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Janssen Research & Development, LLC
- Conditions: Non-Muscle Invasive Bladder Neoplasms
- Interventions: TAR-200; Mitomycin C; Gemcitabine
- Enrollment: 272
- Primary outcome: Disease-free Survival (DFS)

## Commentary we found

- YouTube: 29
- Podcasts: 13
- X threads: 2
- X videos: 1

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=sunrise-5-nct06211764

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT06211764", "email": "<work email>"}; the inbox owner confirms by the emailed link.